Post-translational disruption of dystroglycan–ligand interactions in congenital muscular dystrophies

Overview of attention for article published in Nature, July 2002

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
Above-average Attention Score compared to outputs of the same age and source (64th percentile)

Mentioned by

patent: 18 patents

f1000: 1 research highlight platform

Readers on

mendeley: 181 Mendeley

So far, Altmetric has seen 18 patents that reference this research output.

MULTISPECIFIC BINDING MOLECULES HAVING SPECIFICITY TO DYSTROGLYCAN AND LAMININ-2

Application EP-4659808-A2

European Patent Office

10 Dec 2025

Compositions and methods for treating muscular dystrophy and other disorders

Grant US-12478634-B2

United States of America

25 Nov 2025

BIFUNCTIONAL PROTEINS AND USES THEREOF

Application WO-2025054500-A2

World Intellectual Property Organisation (WIPO)

13 Mar 2025

GENE THERAPY FOR TREATING LIMB GIRDLE MUSCULAR DYSTROPHY R9 AND CONGENITAL MUSCULAR…

Application WO-2024220592-A2

World Intellectual Property Organisation (WIPO)

24 Oct 2024

This page shows the most recent patents that mention this research output. Click here to find out how to access more activity, including 14 additional patents.